12:31 , Jun 13, 2019 |  BioCentury  |  Finance

With $76M series B, BlackThorn looks to build out neurobehavioral platform

BlackThorn has amassed a $76 million series B round from investors who are banking on the potential of its PathFinder platform to circumvent the issue of patient heterogeneity in neurobehavioral disorders. New investors Polaris Partners,...
14:58 , May 30, 2019 |  BioCentury  |  Emerging Company Profile

Thrive’s quest to bring multicancer liquid biopsy test into routine clinical use

With Third Rock leading the way in a $110 million series A, newly launched Thrive is banking that a multi-analyte approach to liquid biopsy could give it an edge in creating a test that is...
09:59 , May 7, 2019 |  BC Innovations  |  Emerging Company Profile

Verve turns CRISPR against cardiovascular disease

Most CRISPR companies are targeting rare genetic disorders, but Verve is breaking from the trend with gene editing therapies for coronary artery disease that could have fewer side effects, greater efficacy and better compliance than...
20:04 , Apr 25, 2019 |  BC Innovations  |  Finance

The academic founders' conundrum

First-time academic entrepreneurs face a circular problem: while they’re continually sought after by VCs and pharmas seeking the next “big thing”, they also face an arduous path to establish their bona fides - not for...
18:29 , Nov 9, 2018 |  BC Week In Review  |  Financial News

Biomatics closes second fund at $300M

Biomatics Capital Partners closed its second fund at $300 million and added Mike Poole and Errik Anderson as venture partners (see "Biomatics' Next Phase" ). Fund II will invest in 15-20 healthcare companies across therapeutics,...
00:10 , Nov 9, 2018 |  BioCentury  |  Finance

Biomatics’ next phase

Biomatics Capital plans to take a more active role in company formation and seek more neuroscience investments with its second fund, and has brought on two partners to implement its strategy. With Fund II, which...
13:02 , Nov 8, 2018 |  BC Extra  |  Financial News

Biomatics closes new fund at $300M

Biomatics Capital Partners closed its second fund at $300 million and added Mike Poole and Errik Anderson as venture partners (see "Biomatics' Next Phase" ). Fund II will invest in 15-20 healthcare companies across therapeutics,...
23:41 , Aug 3, 2018 |  BioCentury  |  Emerging Company Profile

Compass’ range

Compass Therapeutics LLC combines human cell display, high throughput antibody screening and a multispecific engineering platform to develop large libraries of cancer and autoimmune therapies. Traditional approaches to antibody discovery use hybridoma fusions in animals,...
17:32 , Aug 3, 2018 |  BC Week In Review  |  Financial News

Verana Health raises $30M series C

Digital health company Verana Health Inc. (San Francisco, Calif.) raised $30 million on July 31 in a series C round led by new investor GV. Existing investors Biomatics Capital, Brook Byers, GE Ventures and Lagunita...
17:17 , Aug 3, 2018 |  BC Week In Review  |  Financial News

Omniome raises $60M series B

DNA sequencing company Omniome Inc. (San Diego, Calif.) raised $60 million on July 30 in a series B round led by new investors Decheng Capital and Hillhouse Capital Group. New investors Lam Research Capital and...